About Beam Therapeutics Inc
Beam Therapeutics (NASDAQ:BEAM) is at the forefront of developing precision genetic medicines through base editing, a groundbreaking approach to genome editing that enables precise, predictable, and efficient single base changes without making double-stranded breaks in the DNA. This innovative technology has the potential to overcome many of the limitations associated with conventional genome editing methods, offering new possibilities for treating a wide range of genetic diseases. The company's pipeline encompasses projects targeting serious conditions such as sickle cell disease, beta thalassemia, and certain eye disorders, demonstrating its commitment to addressing unmet medical needs. Beam's objective is to leverage its cutting-edge platform to create a new class of genetic medicines that can provide life-long cures to patients suffering from serious diseases.
Snapshot
Operations
Produtos e/ou serviços de Beam Therapeutics Inc
- Development of base editing, a precision gene editing technology that enables the direct, irreversible conversion of a target DNA base into another, offering a less error-prone alternative to CRISPR-Cas9.
- BEAM-101, aimed at treating sickle cell disease by performing precise edits on the HBB gene in hematopoietic stem cells to elevate fetal hemoglobin levels.
- BEAM-102, designed for the treatment of beta-thalassemia, focuses on editing the HBG1 and HBG2 promoters in hematopoietic stem cells to increase fetal hemoglobin expression.
- BEAM-201, a project targeting T-cell malignancies by editing CAR-T cells to enhance their cancer-fighting capabilities and potentially increasing their safety and efficacy.
- Pipeline expansion into liver diseases, utilizing base editing to precisely correct disease-causing mutations in hepatocytes, offering potential treatments for a variety of genetic liver disorders.
- Investment in next-generation base editing technologies to expand the scope and efficiency of current gene editing capabilities, aiming to create more versatile and precise therapies.
equipe executiva do Beam Therapeutics Inc
- Mr. John M. Evans M.B.A.CEO & Director
- Dr. Guiseppe Ciaramella Ph.D.President
- Mr. Sravan Kumar EmanyChief Financial Officer
- Dr. Christine P. Bellon J.D., Ph.D.Senior VP, Chief Legal Officer & Corporate Secretary
- Dr. Amy Simon M.D.Chief Medical Officer
- Dr. Feng Zhang Ph.D.Co-Founder
- Dr. David R. Liu Ph.D.Co-Founder
- Dr. J. Keith Joung M.D., Ph.D.Co-Founder
- Dr. Manmohan Singh Ph.D.Chief Technology Officer
- Dr. Gopi Shanker Ph.D.Chief Scientific Officer